Clinical Trial: TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07836309) titled 'TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)' on Sept. 17.

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).

Study Start Date: Sept. 30

Study Type: OBSERVATIONAL

Condition: Hepatocellular Carcinoma (HCC)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Zhongda Hospital

Information provided by (Responsible Party): Gao-jun Teng, Zhongda Hospital

Published by HT Digital Content Services with permission from He...